China's 30 billion Lung Cancer market, targeting drugs

The World Lung Cancer Alliance launched a global initiative in November 2001, which designated November as the "global lung cancer concern month" Over the years, the incidence rate and mortality rate of lung cancer has ranked the top of the world The annual growth rate of lung cancer in China is 26.9%, and the incidence rate and mortality rate increase year by year According to the latest global cancer treatment trend report released by foreign countries, in 2016, the global market for cancer treatment products and supportive treatment drugs was US $113 billion, up 5.61% year on year It is estimated that by 2021, the global expenditure on anti-tumor drugs and supportive drugs will exceed 147 billion US dollars none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box! Im portant; word-wrap: break-word! Im portant; > rigid demand promotion development, according to the annual report of China Cancer Registry, the incidence of cancer in China shows a continuous upward trend, with the increase of age and immune decline, the incidence rate of malignant tumors shows an upward trend Lung cancer ranks first in the incidence of malignant tumors in China The incidence age of lung cancer has increased rapidly since the age of 40, and reached the peak at the age of 70 Moreover, the prevalence of lung cancer tends to be younger Lung cancer is divided into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) Non-small cell lung cancer is subdivided into adenocarcinoma, squamous cell carcinoma and large cell carcinoma Different types of treatment, recovery and survival rate are quite different The treatment of lung cancer includes surgery, radiotherapy, chemotherapy, biotherapy and immunotherapy At present, the first-line chemotherapy for non-small cell lung cancer is the combination of carboplatin or cisplatin with Taxus or gemcitabine After the advent of targeted small molecule drugs, gefitinib, erlotinib, exetane and pemetrexed disodium as the second-line treatment scheme can benefit the middle-aged and elderly lung cancer patients in the treatment; TiNi drugs have been the pillar varieties of lung cancer chemotherapy drugs Experts believe that in the era of precision medicine, chemotherapy is still the cornerstone of cancer treatment, standardized treatment can improve the survival benefits of patients none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> in the past five years, the new lung cancer pipeline has been screen swiping year by year from 2013 to the first half of 2017, the US FDA has approved 10 new drugs for non-small cell lung cancer treatment (see Table 1) Five of the targeted small molecule drugs are gilotif of bringer ingelham, zykadia of Novartis, tagrisso of AstraZeneca, alecensa of Roche and alunbrid of Takeda The other five antibodies were opdivo, keytruda, cyramza, portrazza and tecentriq of Bristol Myers Squibb Table 1: from 2013 to 2017, FDA approved new drugs for the treatment of non-small cell lung cancer So far, there are seven kinds of small molecule targeted TiNi drugs for lung cancer listed in China (see Table 2) There are four other small molecule targeted Tinian drugs that have not been introduced into China for the treatment of lung cancer, namely zykadia, tagrisso, alecensa and alunbrid, which have been approved by FDA since 2013 Driven by antibody drugs and targeted drugs, the top 20 drugs in the world's original research and sales have reached US $20 billion, up 19.83% year on year Table 2: China's small molecule targeted Tinian drugs for lung cancer: none = "shifumousedownstyle ('shifu_bus_002 ')" style = "margin: 1em Auto; padding: 0px; max width: 100%; color: rgb (62, 62, 62); font family:" hiragino sans GB "," Microsoft YaHei ", Arial, sans serif; font size: 16px; line height: 25.6px; width: 1; border style: none solid; Text align: Center; border bottom width: 1px; border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> China's lung cancer treatment market will face 30 billion yuan in recent years, under the rigid demand of Chinese anti-tumor clinical drugs, a number of lung cancer treatment targeted drugs have been approved for marketing CFDA approved the listing of innovative drugs, such as exetinib and apatinib, which were developed in China, and approved the registration of imported targeted drugs for lung cancer, such as gefitinib, solafeni, erlotinib, clozatinib and afatinib Among them, afatinib is a locally advanced or metastatic non-small cell lung cancer drug for EGFR gene sensitive mutation, which was listed in China in July 2017, and the trade name is GIO Trif) Promote the rapid growth of lung cancer drug treatment market According to the data of minenet, in 2016, the scale of anti-tumor and immune drugs used in three major terminals and six major markets in China reached 129.3 billion yuan, of which 23.843 billion yuan was used in public hospitals in key cities There are more than 40 kinds of Western medicine which have therapeutic effect on lung cancer in hospital In 2016, the effect of public hospitals in key cities on the lung cancer chemotherapy market has reached 7.565 billion yuan, an increase of 10.05% year on year According to conservative calculation, China's lung cancer treatment market has reached 30 billion yuan market scale The top 10 drugs are taxol, docetaxel, pemetrexed, tegio, gemcitabine, bevacizumab, ubenimex, irinotecan, epirubicin and gefitinib The top 10 drugs for lung cancer account for 78% of the chemotherapy market
none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> the rise of small molecule targeted drugs for lung cancer With the advent of the era of precision medicine, anti-tumor drug treatment shows more market characteristics of personalized treatment, differential treatment, targeted treatment, immunotherapy and combination therapy With the improvement of national policy and the awesome improvement of medical insurance year by year, the target drugs have entered the field of vision According to the data statistics of CFDA website, 28 targeted drugs have been registered on the market so far, 8 of which are used for indications of non-small cell lung cancer Bevacizumab, gefitinib, erlotinib, exetinib, clozatinib, afatinib, oxitinib and human endostatin, respectively According to the data of mienei.com, in 2016, the lung cancer targeted drug market of public hospitals in key cities in China reached 1.383 billion yuan, an increase of 14.58% year on year The top 5 drugs are bevacizumab, gefitinib, exetane, sorafenib and human endostatin according to the amount of drug used According to industry estimates, the domestic market has exceeded 5 billion yuan In 2016, small molecule targeted drugs accounted for 62.62% in the lung cancer targeted drug market of public hospitals in key cities in China The new drugs for lung cancer published in the 2017 edition of the national medical insurance catalogue include eight varieties, i.e exetane, gefitinib, recombinant human endostatin, bevacizumab, erlotinib, lapatinib, apatinib and sorafenib, which have completely changed the structure of drugs for lung cancer treatment in the future In the past 10 years, the treatment of lung cancer has made great progress, and the chemotherapy of non-small cell lung cancer has initially formed a consensus Using targeted drugs and cisplatin plus docetaxel, paclitaxel, gemcitabine, vinorelbine and other one or more of them, choosing different combinations, can achieve the purpose of improving curative effect and reducing toxicity none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> gefitinib: gefitinib is a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, which can competitively inhibit tumor cell proliferation, metastasis and neovascularization, improve the symptoms of metastatic non-small cell lung cancer, and thus improve the survival of patients In February 2005, gefitinib from AstraZeneca entered the Chinese market, which has a significant therapeutic effect on patients of Asian origin or no smoking history Before entering the medical insurance market, the market fluctuated greatly, but it was still the leading product in the lung cancer targeted drug market of public hospitals in key cities According to the data of minenet, in 2016, the market of gefitinib, a public hospital in key cities in China, reached 249 million yuan, accounting for 28.05% of small molecule drugs targeted for lung cancer Entering the new health care catalogue will promote the growth of the gefitini market
none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> bevacizumab: bevacizumab is the first humanized monoclonal antibody against vascular endothelial growth factor (VEGF) developed by Roche In 2015, bevacizumab, an anti-tumor angiogenesis drug, was approved by CFDA for the treatment of lung cancer, which is the second indication approved by the drug in China after colorectal cancer It has been confirmed that bevacizumab combined with platinum chemotherapy can lead to clinically significant PFS and OS prolongation in Chinese NSCLC patients It may become a new treatment option and open up a new pattern of lung cancer treatment According to the data of minenet, in 2016, the market of bevacizumab in public hospitals in key cities in China has reached 360 million yuan, an increase of 37.43% over the previous year It is the only drug with high sales volume and high growth rate in the domestic anti-tumor market in 2016 After entering the new medical insurance catalog in 2017, it will promote the continuous growth of the market and bring considerable pressure to the domestic targeted drug market
none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto;